Top-Rated Stocks NASDAQ:PCRX Pacira BioSciences - PCRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $39.91 -0.16 (-0.40%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$39.24▼$40.4050-Day Range$35.53▼$43.3852-Week Range$35.35▼$82.16Volume293,827 shsAverage Volume557,597 shsMarket Capitalization$1.83 billionP/E Ratio128.74Dividend YieldN/APrice Target$64.36 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Pacira BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside61.3% Upside$64.36 Price TargetShort InterestHealthy7.31% of Shares Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews Sentiment0.99Based on 4 Articles This WeekInsider TradingSelling Shares$20,917 Sold Last QuarterProj. Earnings Growth56.04%From $2.73 to $4.26 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.92 out of 5 starsMedical Sector22nd out of 1,002 stocksPharmaceutical Preparations Industry7th out of 488 stocks 4.4 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.36, Pacira BioSciences has a forecasted upside of 61.3% from its current price of $39.91.Amount of Analyst CoveragePacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.31% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 5.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 67.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.42. Previous Next 3.9 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pacira BioSciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,917.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Pacira BioSciences is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 56.04% in the coming year, from $2.73 to $4.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 128.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 128.74, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 123.33.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacira BioSciences (NASDAQ:PCRX) StockPacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Read More Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comThird Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. LawsuitMarch 24, 2023 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) shareholders have lost 49% over 1 year, earnings decline likely the culpritMarch 29, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 21, 2023 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Moderate Buy" from AnalystsMarch 9, 2023 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare ConferenceMarch 1, 2023 | msn.comPacira's (PCRX) Q4 Earnings Match Estimates, Revenues FallMarch 1, 2023 | markets.businessinsider.comAnalyst Expectations for Pacira BioSciences's FutureMarch 29, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 1, 2023 | finance.yahoo.comQ4 2022 Pacira Biosciences Inc Earnings CallFebruary 27, 2023 | msn.comEarnings Preview For Pacira BioSciencesFebruary 23, 2023 | finance.yahoo.comLPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management SolutionsFebruary 23, 2023 | uk.finance.yahoo.comPacira Pharmaceuticals, Inc. (PCRX)February 21, 2023 | finance.yahoo.comPacira to Report 2022 Financial Results on Tuesday February 28, 2023January 7, 2023 | seekingalpha.comPacira BioSciences: More Evidence Needed To Advocate Entry At Current ValuationsJanuary 5, 2023 | finance.yahoo.comPacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 MillionJanuary 4, 2023 | finance.yahoo.comPacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?December 20, 2022 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)December 13, 2022 | finance.yahoo.comPacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022November 23, 2022 | msn.comPacira BioSciences's Return On Capital Employed InsightsNovember 18, 2022 | finance.yahoo.comWill Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?November 17, 2022 | finance.yahoo.comNew Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on PatientsNovember 14, 2022 | finance.yahoo.comPacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022November 9, 2022 | finance.yahoo.comPacira BioSciences Third Quarter 2022 Earnings: EPS Misses ExpectationsNovember 8, 2022 | finance.yahoo.comPacira BioSciences to Present at Two Healthcare Conferences in NovemberNovember 4, 2022 | finance.yahoo.comPacira's (PCRX) Q3 Earnings Miss Estimates, Revenues BeatSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Company Calendar Last Earnings2/28/2023Today3/28/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees697Year FoundedN/APrice Target and Rating Average Stock Price Forecast$64.36 High Stock Price Forecast$80.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+62.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.31 Trailing P/E Ratio127.90 Forward P/E Ratio14.52 P/E GrowthN/ANet Income$15.91 million Net Margins2.39% Pretax Margin1.99% Return on Equity11.09% Return on Assets4.74% Debt Debt-to-Equity Ratio0.85 Current Ratio3.37 Quick Ratio2.72 Sales & Book Value Annual Sales$666.82 million Price / Sales2.73 Cash Flow$4.07 per share Price / Cash Flow9.74 Book Value$16.89 per share Price / Book2.35Miscellaneous Outstanding Shares45,950,000Free Float43,149,000Market Cap$1.82 billion OptionableOptionable Beta0.77 Key ExecutivesDavid M. StackChairman & Chief Executive OfficerDaryl J. GauglerChief Operating OfficerCharles A. ReinhartChief Financial OfficerRoy WinstonChief Medical OfficerCharles Anthony LaranjeiraChief Technical OfficerKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNCorcept TherapeuticsNASDAQ:CORTPerrigoNYSE:PRGOAkero TherapeuticsNASDAQ:AKROAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsLoring Wolcott & Coolidge Fiduciary Advisors LLP MASold 15,534 shares on 3/2/2023Ownership: 0.078%Voya Investment Management LLCSold 115,661 shares on 2/28/2023Ownership: 0.439%Teachers Retirement System of The State of KentuckyBought 1,135 shares on 2/22/2023Ownership: 0.069%Macquarie Group Ltd.Sold 896,749 shares on 2/21/2023Ownership: 4.440%Point72 Middle East FZEBought 11,622 shares on 2/16/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions PCRX Stock - Frequently Asked Questions Should I buy or sell Pacira BioSciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks. What is Pacira BioSciences' stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year price objectives for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they anticipate the company's stock price to reach $64.36 in the next year. This suggests a possible upside of 62.3% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts. How have PCRX shares performed in 2023? Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX shares have increased by 2.7% and is now trading at $39.65. View the best growth stocks for 2023 here. When is Pacira BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our PCRX earnings forecast. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Tuesday, February, 28th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.71 by $0.11. The firm earned $171.96 million during the quarter, compared to the consensus estimate of $174.12 million. Pacira BioSciences had a net margin of 2.39% and a trailing twelve-month return on equity of 11.09%. What ETFs hold Pacira BioSciences' stock? ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Horizon Managed Volatility Small/Mid ETF (HSMV) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). What guidance has Pacira BioSciences issued on next quarter's earnings? Pacira BioSciences updated its FY22 earnings guidance on Thursday, January, 5th. The company provided earnings per share (EPS) guidance of at least $2.50 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $666.8 million, compared to the consensus revenue estimate of $676.64 million. What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA). What is Pacira BioSciences' stock symbol? Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX." Who are Pacira BioSciences' major shareholders? Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Macquarie Group Ltd. (4.44%), Armistice Capital LLC (4.12%), Baillie Gifford & Co. (4.06%), Renaissance Technologies LLC (3.46%), Stephens Investment Management Group LLC (2.55%) and Millennium Management LLC (2.51%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pacira BioSciences' stock price today? One share of PCRX stock can currently be purchased for approximately $39.65. How much money does Pacira BioSciences make? Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.82 billion and generates $666.82 million in revenue each year. The company earns $15.91 million in net income (profit) each year or $0.31 on an earnings per share basis. How many employees does Pacira BioSciences have? The company employs 697 workers across the globe. How can I contact Pacira BioSciences? Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049. This page (NASDAQ:PCRX) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.